This is the authors' abstract. We don't add key points for this paper.
Based on the results of registration studies, the drug cabozantinib, the mechanism of action of which is determined by the inhibition of tyrosine kinases on a relatively wide range of cellular receptors, is registered in the treatment of hepatocellular cancer, kidney cancer and thyroid cancer. This literature review collects data on the mechanism of action, the results of preclinical experiments and phases I–III studies. Emphasis is placed on the tolerability and efficacy of the drug in the population of hepatocellular cancer patients.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
М. Yu. Fedyanin (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: